ImmunoGen, Inc.
Oct 23, 2008

ImmunoGen, Inc. Announces Webcast of Presentation at the 7th Annual BioInvestor Forum


ImmunoGen, Inc. (Nasdaq: IMGN) today announced that its presentation at the 7th Annual BioInvestor Forum will be webcast live. The presentation is scheduled to begin at 8:30 a.m. PDT on October 30, 2008, and will be given at the Palace Hotel, San Francisco, CA. The presentation will provide an update on ImmunoGen.

The webcast can be accessed through the "Investor Information" section of the ImmunoGen website, Following the live webcast, a replay of the presentation will be available at the same location until November 7, 2008.

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using its expertise in cancer biology, monoclonal antibodies and the creation and attachment of potent cell-killing agents. The Company's Tumor-Activated Prodrug (TAP) technology uses antibodies to deliver one of ImmunoGen's proprietary cell-killing agents specifically to cancer targets. In addition to the Company's proprietary clinical pipeline, ImmunoGen collaborators Genentech, sanofi-aventis, Biogen Idec, and Biotest also are testing TAP compounds in the clinic, and a naked antibody is in clinical trials through the Company's collaboration with sanofi-aventis. Other ImmunoGen collaborative partners include Bayer HealthCare and Amgen.

Source: ImmunoGen, Inc.